Orion Oyj (FRA:OFK)

Germany flag Germany · Delayed Price · Currency is EUR
59.60
-0.95 (-1.57%)
Last updated: Dec 5, 2025, 8:04 AM CET
33.57%
Market Cap 8.55B
Revenue (ttm) 1.63B
Net Income (ttm) 313.20M
Shares Out n/a
EPS (ttm) 2.23
PE Ratio 27.29
Forward PE 17.30
Dividend 1.64 (2.53%)
Ex-Dividend Date Oct 15, 2025
Volume n/a
Average Volume 4
Open 59.60
Previous Close 60.55
Day's Range 59.60 - 59.60
52-Week Range 41.55 - 71.75
Beta n/a
RSI 46.09
Earnings Date Feb 12, 2026

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflammatory pain; Divina series for menopausal symptoms; Simdax for acute decompensated heart failure; Fareston for breast cancer; Trexan for rheumatoid art... [Read more]

Industry Pharmaceutical Preparations
Founded 1917
Employees 3,880
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol OFK
Full Company Profile

Financial Performance

In 2024, Orion Oyj's revenue was 1.54 billion, an increase of 29.65% compared to the previous year's 1.19 billion. Earnings were 329.90 million, an increase of 52.17%.

Financial Statements

News

There is no news available yet.